Cancer BiologybioRxivPreprint
Targeting a broad spectrum of KRAS-mutant cancers by hyperactivation-induced cell death
J. Lilja, J. Kaivola, J. R. W. Conway…·J. Ivaska
This study identifies SHANK3 as a RAS interactor that limits oncogenic KRAS signaling, and shows that disrupting its interaction with KRAS induces cell death in KRAS-mutant cancers.
DOI 10.1101/2022.09.21.508660